论文部分内容阅读
为评价氯雷他定对哮喘儿童血浆P-选择素表达的抑制作用及临床应用的意义。应用~(125)I-SZ-51标记的特异性单克隆抗体放免法,测定60例急性发作期和缓解期哮喘患儿血浆P-选择素水平。随机分成治疗组(30例),采用吸入激素+氯雷他定治疗×24周;对照组(30例)单用吸入激素治疗。结果显示:缓解期,治疗组血浆P-选择素水平、肺功能、临床综合评分均较对照组明显下降和改善,差异显著(P均<0.01)。提示氯雷他定具有抑制P-选择素表达的作用,能有效地减轻变应性炎症,改善哮喘儿童的临床症状和肺功能,可作为辅佐治疗儿童支气管哮喘的药物之一。
To evaluate the inhibitory effect of loratadine on plasma P-selectin expression in asthmatic children and its clinical significance. The plasma levels of P-selectin in 60 children with acute exacerbation and remission were measured by radioimmunoassay using ~ (125) I-SZ-51 labeled monoclonal antibody. Randomly divided into treatment group (30 cases), inhaled hormone + loratadine treatment × 24 weeks; control group (30 cases) were treated with inhaled corticosteroids alone. The results showed that the plasma P-selectin level, lung function and clinical comprehensive score of the treatment group were significantly decreased and improved compared with the control group in the remission period (P <0.01). It suggested that loratadine could inhibit the expression of P-selectin, alleviate the allergic inflammation and improve the clinical symptoms and lung function of asthmatic children. It may be used as adjuvant to treat bronchial asthma in children.